



Drug-induced Parkinsonism (DIP) is the second most com-
mon cause of parkinsonism (PK)1. Flunarizine and cinnarizine in-
duced parkinsonism (FCIP) is one of the most frequent forms and 
is commonly found in elderly female patients manifesting sym-
metrical motor symptoms with resting and/or postural trem-
or, often associated with depression, and occasionally acathisia 
and dyskinesia 1.
FCIP was first described in Brazil in 1984 by De Melo-Souza 
during the IX Brazilian Congress of Neurology2. In his study, De 
Melo-Souza reported 5 female elderly patients with a past his-
tory of flunarizine use presenting with both PK and depression. 
A few years later, in 1989, De Melo-Souza and Ragazzo present-
ed a larger series at the Annual Meeting of the American Acad-
emy of Neurology. In that series, all of the 28 patients (25 fe-
male, with a mean age of 66 years) had used flunarizine 10 mg 
daily for a mean time of 6 months. Along with a rigid-akinet-
ic syndrome, 60% of the patients had tremor and 85% had de-
pression. Only one patient presented with bucolingual dyskine-
sia and six had akathisia1.
According to Negrotti and Calzetti3 and Martí-Masso and Poza4 
the clinical characteristics of cases with FCIP include: 1) Previous 
flunarizine or cinnarizine treatment; 2)  PK diagnosed after onset 
of therapy with the drugs; 3) Clinical features are indistinguishable 
from Parkinson’s disease, with a rigidity-akinetic syndrome, resting 
and postural tremor, but usually with bilateral onset, progressing 
with symmetrical findings and associated depressive disorder; 4) 
Predominantly affects elderly female patients; 5) Remission of PK 
symptoms after drug discontinuation; 6) Other causes of PK (in-
cluding other drugs) excluded. Curiously, the first cases presented 
by De Melo-Souza 25 years ago with the main clinical features of 
FCIP were reported by him as “the crying older little women”1,2,5. 
Twenty-five years later, FCIP is widely recognized as one of 
the most common cause of PK and it is now being called as De 
Melo e Souza’s syndrome1,5.
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